Gilead to Pay Merck $2.5 Billion in Record Patent Judgment Over Hep C Therapies

Drug Industry Daily
A A
Gilead will have to pay Merck $2.5 billion for infringing a patent that covers the active ingredient of its blockbuster hepatitis C drugs, Salvadi and Harvoni, in the country’s largest ever judgment for an infringement.

To View This Article:

Login

Subscribe To Drug Industry Daily